Should I Buy BLRX? BLRX 2026 Analysis

Should You Buy BioLine RX Ltd (BLRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.170

1 Day change

5.32%

52 Week Range

7.770

Analysis Updated At

2026/01/28

Not a good buy right now for a beginner, long-term investor who wants to act immediately. BLRX is trading near resistance with momentum starting to cool, while the latest (2025/Q3) fundamentals show a severe revenue decline (-91% YoY). Options imply extremely high uncertainty (very high IV) without strong confirming volume—this is more speculative than long-term-investor-friendly at this moment.

Technical Analysis

Price/Trend: BLRX is up +3.61% today to 3.085, but pre-market was down (-1.96%), suggesting some near-term choppiness. Momentum: MACD histogram is positive (0.0384) but “positively contracting,” which often signals bullish momentum is weakening. RSI: RSI(6)=66.23 (upper-neutral, close to overbought), implying limited immediate upside before a pullback is likely. Moving averages: Converging MAs = no strong, clean trend; more range-bound behavior. Key levels: Pivot 2.942. Resistance R1 3.121 (very close to current price); R2 3.232. Support S1 2.762 then S2 2.651. With price near R1, the risk/reward for an immediate long-term entry is not attractive. Pattern-based bias: Similar-pattern projection shows +6.9% next week potential but slightly negative next month (-0.46%), reinforcing a short-term pop risk rather than a clean long-term setup. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call ratio is very low (0.11), which is generally bullish (more calls than puts outstanding). However, today’s options activity is extremely light (total volume 2; put volume 0), so the signal is weak. Volatility: Implied vol (30D) ~509% vs historical vol ~56% indicates the market is pricing extreme uncertainty/event risk. IV percentile 66.67 suggests elevated (not rare, but high). This is consistent with a speculative biotech-style profile rather than a stable long-term compounder setup.

Technical Summary

Sell

Buy

Positive Catalysts

Options open interest skew is call-heavy (OI put/call 0.11), which can reflect bullish positioning.
If BLRX breaks and holds above ~3.12 (R1), a momentum push toward ~3.23 (R2) becomes more plausible.
Hedge fund and insider activity are neutral (no active selling pressure indicated by the provided trend data).

Neutral/Negative Catalysts

Technical setup is not ideal for an immediate long-term buy: price is pressing into resistance (R1 3.121) with MACD momentum contracting and RSI near overbought.
Extremely high implied volatility (509%) signals high uncertainty; without strong option volume confirmation, it’s not a clean sentiment signal.
No news/catalysts in the past week to justify a durable re-rating.

Financial Performance

Latest quarter: 2025/Q3. Revenue: 427K, down -91.36% YoY (major top-line deterioration). Net income: -977K (still a loss; trend described as down -83.22% YoY in the snapshot). Gross margin: 80.33%, down -3.65% YoY. Overall: The quarter shows severe revenue contraction and continued losses—not the kind of growth profile that typically fits a beginner’s long-term, buy-now decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating changes or price target updates were provided, so a Wall Street consensus view can’t be validated here. Pros (if any) would likely hinge on future catalysts not shown in this dataset; cons based on provided data are weak revenue trends and high uncertainty (very high IV).

1 Analyst Rating

Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.010

Low

Averages

High

Current: 3.010

Low

Averages

High

Jones Trading

Justin Walsh

Strong Buy

Hold

Downgrades

n/a

AI Analysis

2025-04-02

Reason

Jones Trading

Justin Walsh

Price Target

n/a

AI Analysis

2025-04-02

Downgrades

Strong Buy

Hold

Reason

JonesResearch analyst Justin Walsh downgraded BioLineRx to Hold from Buy without a price target following the Q4 report. BioLineRx is on "sounder financial footing" following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company's pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$9 → $26

2025-03-31

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$9 → $26

2025-03-31

Maintains

Strong Buy

Reason

BLRX Should I Buy

BLRX Should I Buy

Should You Buy BioLine RX Ltd (BLRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch